Sofgen Pharma S.A. (PROCF)
| Market Cap | 57.83M -80.7% |
| Revenue (ttm) | 423.75M +5.1% |
| Net Income | 40.34M +11.7% |
| EPS | 0.40 +11.8% |
| Shares Out | 2.30B |
| PE Ratio | 0.06 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 1,099 |
| Open | 0.0251 |
| Previous Close | 0.0251 |
| Day's Range | 0.0251 - 0.0251 |
| 52-Week Range | 0.0101 - 1.6000 |
| Beta | 63.09 |
| RSI | 46.58 |
| Earnings Date | May 15, 2026 |
About Sofgen Pharma
Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision car... [Read more]
Full Company ProfileFinancial Performance
In 2023, Sofgen Pharma's revenue was $423.75 million, an increase of 5.10% compared to the previous year's $403.20 million. Earnings were $40.34 million, an increase of 11.67%.
Financial StatementsNews
Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership
New Investors Take Over the Strategic Leadership as Headquarters Move to Bogotá, Marking the Start of a New Chapter of Growth, Execution, and Transformation under Enhanced Governance
Nasdaq delists Colombia's Procaps Group due to financial shortfalls
Nasdaq recently announced the removal of the Procaps Group due to its failure to complete financial reporting standards on time, a significant decision that illustrates the difficulty that businesses ...